Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In recognition of the new links with the Nuffield Department of Clinical Neurosciences and the Department of Experimental Psychology, the Oxford Clinical Trials Unit for Mental Illness (OCTUMI) has a new name: the Oxford Cognitive Health and Neuroscience Clinical Trials Unit (OCHNCTU, pronounced oc-n-tü) and a new logo.

The OCHNCTU portfolio will, in future, include trials for neurological conditions and cognitive neuroscience. The CTU offers advice and support in all aspects of the planning, conducting and reporting of clinical trials. Key areas of expertise include statistics, trial management, quality assurance, database provision and data management. Where resources permit, specific services (such as a randomisation program or trial monitoring) can be provided.

 

OCHNCTU projects include both non-commercial efficacy trials designed to reduce the uncertainties associated with current treatments and early phase trials evaluating potential new treatments. The CTU is working closely with the Oxford NHS Trusts to increase research productivity and recruitment into trials and has links with TVCLRN, DeNDRoN, the MHRN and other Oxford University Clinical Trials Units. OCHNCTU is also closely affiliated to the Oxford Cognitive Health Clinical Research Facility which supports the translation of neuroscience discoveries into effective therapies. 

For more information, contact Dr Jennifer Rendell on 01865 226465, email ochnctu@psych.ox.ac.uk

Similar stories

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.